Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada
NCT ID: NCT04080856
Last Updated: 2022-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2019-12-04
2021-09-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
NCT00619866
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
NCT00797225
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
NCT01760954
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
NCT02143713
Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
NCT04630990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with endometriosis
Premenopausal participants with endometriosis receiving elagolix in real-world setting
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Naive to elagolix prior to starting this study or have stopped taking elagolix for 2 months prior to the start of this study
* Symptomatic endometriosis (clinically or surgically diagnosed) including currently experiencing dysmenorrhea
* Has provided written informed consent allowing the use of their data for the study
Exclusion Criteria
* Cannot fill out questionnaires
* Prescribed elagolix for a period of 1 or 2 months only
* Post-menopausal (naturally or surgically)
* Symptomatic uterine fibroid(s)
* Had medical treatment for uterine fibroids (any length of treatment)
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Health Campus Rheumatology Clinic /ID# 213065
Calgary, Alberta, Canada
Aubrey D. Uretsky Professional Corporation /ID# 214753
Edmonton, Alberta, Canada
BC Women's Hospital /ID# 214561
Vancouver, British Columbia, Canada
Strand Clinic /ID# 213567
St. John's, Newfoundland and Labrador, Canada
IWK Health Center /ID# 213066
Halifax, Nova Scotia, Canada
Medicor Research Inc /ID# 213467
Greater Sudbury, Ontario, Canada
Hamilton Health Sciences - McMaster University Medical Centre /ID# 213496
Hamilton, Ontario, Canada
Dr. George A. Vilos Medicine Professional Corporation /ID# 214497
London, Ontario, Canada
Ottawa Hospital Research Institute /ID# 213608
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Ctr /ID# 214330
Toronto, Ontario, Canada
Unity Health Toronto - St. Michael's Hospital /ID# 213590
Toronto, Ontario, Canada
CISSS - Hôpital de Gatineau /ID# 212944
Gatineau, Quebec, Canada
Jessima R&D Inc. /ID# 212943
LaSalle, Quebec, Canada
Clinique de Gynecologie-Obstetrique Pierre Boucher /ID# 213064
Longueuil, Quebec, Canada
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 213439
Montreal, Quebec, Canada
Jewish General Hospital /ID# 215728
Montreal, Quebec, Canada
Duplicate_Brunswick Medical /ID# 214743
Montreal, Quebec, Canada
CHU de Quebec-Université Laval hôpital CHUL /ID# 213677
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P19-933
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.